Table 1.

Clinical characteristics and baseline laboratory results.

Number of patients, n	72
Female, n (%)	25 (35%)
White race, n (%)	65 (90%)
Age at infusion 1, years (mean, SD)	13.6 (4)
Disease duration, days (median, IQR)	51 (17-362)
<90 days, n (%)	44 (61%)
Previous surgery, n (%)	4 (5.6%)
Concomitant IMM, n (%)	2 (3%)
Concomitant prednisone, n (%)	44 (61%)
Time on prednisone, days (median, IQR)	18 (7-43)
Crohn’s location
Ileal only, n	6
Colon only, n	9
Ileocolonic, n	57
Crohn’s behavior
Inflammatory	61
Stricturing	7
Penetrating	3
Both stricturing/penetrating	1
Perianal Crohn’s, n (%)	11 (15%)
Starting dose, mg/kg (median, IQR)	5.8 (5.2-6.6)
BMI kg/m2 (median, IQR)	17.6 (15.4-20.9)
BMI z-score (median, IQR)	−0.69 (−1.4 to 0.17)
wPCDAI (mean, SD)	46 (28)
ESR mm/hr. (median, IQR)	18 (10-38)
CRP mg/dL (median, IQR)	1.1 (0.28-2.1)
Albumin g/dL (mean, SD)	3.3 (0.6)
Fecal calprotectin μg/g (median, IQR)	2160 (1009-2501)

Imm, immunomodulator; BMI, body mass index; wPCDAI, weighted Crohn’s disease activity index; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein.